Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor

Alavi, Parnian; Rathod, Abhisha M.; Jahroudi, Nadia

doi:10.3390/jcm10184190

Cited by 12 publications

(10 citation statements)

References 203 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Von Willebrand factor (VWF) is a multisubunit protein that anchors platelets to subendothelial collagen. It serves as a carrier protein for the VIII factor in plasma, and endothelial cell release of VWF plays an essential role in the formation of platelet aggregates and thrombosis and is closely associated with aging ( Alavi, Rathod & Jahroudi, 2021 ). We found that VWF was upregulated in the AAA (aged) group (compared with the normal (aged) group or the AAA (aged) group), suggesting that it might be associated with aging and AAA formation.…”

Section: Discussionmentioning

confidence: 99%

“…In previous studies, VWF was found to be expressed in aneurysm tissue and colocalized with hepatocyte growth factor (HGF) in the most severe part of the aneurysm-injured wall ( Shintani et al, 2011 ). As age increases, VWF levels increase significantly, and thrombosis events increase significantly ( Alavi, Rathod & Jahroudi, 2021 ). Fibrinogen is a vital protein involved in the processes of coagulation and hemostasis and plays a crucial role in the process of AAA formation, and fibrinogen has been proven to be a plasma biomarker of AAA formation and progression ( Sundermann et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ageing- and AAA-associated differentially expressed proteins identified by proteomic analysis in mice

Ren

Tang

et al. 2022

PeerJ

View full text Add to dashboard Cite

Background Abdominal aortic aneurysm (AAA) is a disease of high prevalence in old age, and its incidence gradually increases with increasing age. There were few studies about differences in the circulatory system in the incidence of AAA, mainly because younger patients with AAA are fewer and more comorbid nonatherosclerotic factors. Method We induced AAA in ApoE−/− male mice of different ages (10 or 24 weeks) and obtained plasma samples. After the top 14 most abundant proteins were detected, the plasma was analyzed by a proteomic study using the data-dependent acquisition (DDA) technique. The proteomic results were compared between different groups to identify age-related differentially expressed proteins (DEPs) in the circulation that contribute to AAA formation. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein–protein interaction (PPI) network analyses were performed by R software. The top 10 proteins were determined with the MCC method of Cytoscape, and transcription factor (TF) prediction of the DEPs was performed with iRegulon (Cytoscape). Results The aortic diameter fold increase was higher in the aged group than in the youth group (p < 0.01). Overall, 92 DEPs related to age and involved in AAA formation were identified. GO analysis of the DEPs showed enrichment of the terms wounding healing, response to oxidative stress, regulation of body fluid levels, ribose phosphate metabolic process, and blood coagulation. The KEGG pathway analysis showed enrichment of the terms platelet activation, complement and coagulation cascades, glycolysis/gluconeogenesis, carbon metabolism, biosynthesis of amino acids, and ECM-receptor interaction. The top 10 proteins were Tpi1, Eno1, Prdx1, Ppia, Prdx6, Vwf, Prdx2, Fga, Fgg, and Fgb, and the predicted TFs of these proteins were Nfe2, Srf, Epas1, Tbp, and Hoxc8. Conclusion The identified proteins related to age and involved in AAA formation were associated with the response to oxidative stress, coagulation and platelet activation, and complement and inflammation pathways, and the TFs of these proteins might be potential targets for AAA treatments. Further experimental and biological studies are needed to elucidate the role of these age-associated and AAA-related proteins in the progression of AAA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ageing- and AAA-associated differentially expressed proteins identified by proteomic analysis in mice

Ren

Tang

et al. 2022

PeerJ

View full text Add to dashboard Cite

show abstract

“…According to our results, there was no significant difference in plasma VWF between the RVO and age-matched controls at the baseline. Several researchers have reported that plasma VWF increased not only in patients with hypertension and arteriosclerosis but also in healthy individuals with aging [28,29].…”

Section: Discussionmentioning

confidence: 99%

Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema

Hirai

Yamashita

Matsumoto

et al. 2022

Preprint

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is a major retinal disease accompanied by venous thrombosis. Although several studies have proposed an association between venous thrombosis and von Willebrand factor (VWF), the association between RVO and VWF remains unclear. We aimed to investigate the association between RVO and VWF and the alteration of VWF levels under the anti-vascular endothelial growth factor (VEGF) treatment. We enrolled 55 patients with RVO involved cystoid macular edema. They received intravitreal injection of anti-VEGF drugs, either ranibizumab or aflibercept. We examined the clinical data, measured plasma VWF: antigen (VWF: Ag) and plasma a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (ADAMTS13: AC) and analyzed them to identify variabilities during the treatment. At the baseline there was no significant difference between the RVO group and age-matched controls in both VWF: Ag and ADAMTS13: AC levels but ADAMTS13:AC was significantly lower in central RVO (CRVO) than in branch RVO (BRVO) ( P = 0.015). In BRVO, the negative correlation was found between VWF: Ag and central choroidal thickness (CCT) (r = −0.51, P < 0.001). In BRVO after the anti-VEGF treatment, VWF: Ag decreased significantly from 134% at the baseline to 109% at 1 day after ( P = 0.002) and to 107% at 1 month after ( P = 0.030). In contrast, ADAMTS13: AC showed no significant difference during this period. In BRVO at 1 month after treatment, we found a negative correlation between VWF: Ag and CCT (r = −0.47, P = 0.001). Our findings suggest an association between VWF and CCT in patients with BRVO, thus the measurement of VWF may be useful for evaluating the disease activity and prognosis.

show abstract

“…According to our results, plasma VWF was not significant between the RVO group and age-matched controls at baseline. Several researchers have reported that plasma VWF increases not only in patients with hypertension and arteriosclerosis but also in healthy individuals with aging [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema

et al. 2022

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is a major retinal disease caused by venous thrombosis. Although several studies have proposed an association between venous thrombosis and von Willebrand factor (VWF), the association between RVO and VWF remains unclear. We aimed to investigate the association between RVO and VWF and the alteration of VWF levels under anti-vascular endothelial growth factor (VEGF) treatment. We enrolled 55 patients with RVO involved cystoid macular edema. They received intravitreal injection of anti-VEGF drugs, either ranibizumab or aflibercept. We examined the clinical data and measured plasma VWF antigen and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity to identify variabilities during treatment. At baseline, there was no significant difference between the RVO group and age-matched controls in both VWF antigen and ADAMTS13 activity levels, but ADAMTS13 activity was significantly lower in central RVO than in branch RVO (P = 0.015). In branch RVO, VWF antigen was negatively correlated with central choroidal thickness (r = −0.51, P < 0.001). In branch RVO after anti-VEGF treatment, VWF antigen levels decreased significantly from 134% at baseline to 109% at 1 day (P = 0.002) and 107% at 1 month (P = 0.030) after treatment. In contrast, ADAMTS13 activity showed no significant difference during this period. In branch RVO at 1 month after treatment, VWF antigen was negatively correlated with central choroidal thickness (r = −0.47, P = 0.001). Our findings suggest an association between VWF and central choroidal thickness in patients with branch RVO, thus the measurement of VWF may be useful for evaluating disease activity and prognosis.

show abstract

Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor

Cited by 12 publications

References 203 publications

Ageing- and AAA-associated differentially expressed proteins identified by proteomic analysis in mice

Ageing- and AAA-associated differentially expressed proteins identified by proteomic analysis in mice

Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema

Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema

Contact Info

Product

Resources

About